Checks heart artery disease risk in people treated for past cancer
Checks heart artery disease risk using heart scans in cancer survivors.
Plain-language title generated from the registry record
Registry title: Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer
Key facts
- Where
- Hobart and Melbourne, AustraliaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 70 years old?
Source: NCT05366153, who can take part
Where in Australia
- Tom MarwickHobart, AustraliaTaking people
- Baker Heart and Diabetes InstituteMelbourne, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Baker Heart and Diabetes Institute
- Trial code
- NCT05366153
- Record updated
- 4 December 2025
- Original description
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago.Read full original descriptionShow less
Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer (REDEEM-CAD)
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy >5 years ago.
Inclusion: A history of cancer >5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).
Exclusion: History of previous coronary artery disease; Contraindications/Intolerance to or already taking statin therapy; Known coronary artery disease at recruitment; Oncologic (or other) life expectancy <12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial; Unable to provide written informed consent to participate in this study; Inability to acquire interpretable CT images.